THIS WEEK, Quest Diagnostics Incorporated will issue its fourth quarter and full year 2012 financial report. In anticipation of this, the nation’s largest lab company has been cleaning out its closets, so to speak.
With its new CEO finishing out his first eight months of service, Quest Diagnostics is taking the opportunity to dispose of some
CEO SUMMARY: Anatomic pathology groups across the nation must develop effective strategies to address challenges in pricing, intensifying competition, and expensive new technologies. That’s the assertion of three pathology practice administrators who have organized a boot camp in Dallas next month specifically to train other practice administrators and managers. This event will provide administrators from
IT WAS A BUSY TIME LAST WEEK on the lab industry meeting circuit. THE DARK REPORT made the rounds and uncovered some valuable intelligence for lab directors and pathologists.
First on the meeting tour was Philadelphia, site of the American Association of Clinical Chemistry (AACC) annual convention, held July 21-25. The number of exhibitors and the size
CEO SUMMARY: Dissident shareholders and a crushing debt burden are the reason Medical Arts Laboratory decided to file for reorganization under Chapter 11 bankruptcy laws. Both factors are the legacy of an ill-fated attempt to create a national laboratory organization between 1994 and 1997. It’s the story of a business strategy that brought Medical Arts
CEO SUMMARY: It’s no secret that a handful of laboratory companies would like to complete an initial public offering (IPO). If Specialty Labs’ public offering goes well, expect these lab companies to bring their own stock offerings to the public equity markets. As the number of public lab companies increases, the competitive marketplace for laboratory
CEO SUMMARY: Pathology Partners, Inc. got a new President and CEO this month. The company is organized to build and operate independent regional histology and cytology laboratories in support of anatomic pathologists. Its business model is different than competing pathology companies and Pathology Partners believes that it will be well-positioned as integrated clinical care becomes
AMERIPATH INKS PACT WITH MEDAPHIS, BUYS FLORIDA PATH PRACTICE
Things are busy at AmeriPath, Inc. of Riviera Beach, Florida. The pathology practice management company announced a number of accomplishments.
First, it signed an agreement with Medaphis Corporation of Atlanta. Medaphis will provide “comprehensive reimbursement services” for 20 AmeriPath practice locations. These will include billing, AR, and enhanced
CEO SUMMARY: Our story picks for 1998 demonstrate a broad range of subjects. Each affects laboratories and pathology practices in significant ways and should be used to trigger appropriate management strategies. Two essential themes among this year’s ten biggest lab stories: continued downward squeeze on reimbursement and a flood of new technology is on the
THIRD IN A SERIES
WHAT DOES IT MEAN WHEN the largest companies in a multibillion dollar industry announce that they will “get out” of that business?
That is the question which must be answered after MedPartners, Inc. joined PhyMatrix Corp. in publicly declaring that they would abandon the physician practice management (PPM) business.
MedPartners announced its decision on
PHYSICIAN PRACTICE MANAGEMENT (PPM) companies have arrived at pathology’s doorstep. For better or worse, a new era is pushing its way into the pathology profession.
In the first installment of this exclusive DARK REPORT series, we exposed the rotten secret behind the “growth by acquisition” strategy. “Acquisition only” strategies are no guarantee of ongoing financial stability.